Can gentle sensory therapy soothe severe schizophrenia?

NCT ID NCT07769749

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial asks whether basal stimulation therapy—a gentle approach using touch and sensory cues—can improve the health and well-being of adults with schizophrenia who live in permanent institutional care. Participants, aged 55 and older with long-standing schizophrenia, will receive either standard physiotherapy alone or physiotherapy plus basal stimulation twice a week for six weeks. Researchers will measure changes in consciousness, cognitive function, and blood markers to see if this therapy offers added benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
basal stimulation therapy (a gentle sensory-based therapy) combined with standard physiotherapy
What this could lead to
If effective, this therapy could offer a drug-free way to ease anxiety and improve quality of life for people with severe schizophrenia in long-term care.
What could go wrong
This is a very small early-stage study (12 participants), so results may not apply broadly. The therapy is gentle, but its benefits remain unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Psychiatric Hospital SPZOZ in Rybnik, Poland

    Rybnik, Silesian Voivodeship, 44-200, Poland

  • Jerzy Kukuczka Academy of Physical Education in Katowice, Poland

    Katowice, Silesian Voivodeship, 40-065, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.